Research output per year
Research output per year
Personal profile
Research interests
Dr. Prasad serves as Director of Clinical Theranostics in the Division of Nuclear Medicine, Mallinckrodt Institiute of Radiology. His Research interests include Clinical theranostics, Translational theranostics and Clinical trial design of Phase 1-Phase 3 trials in theranostics.
Education activities and interests
Prior to joining Washington University in St Louis, I have been involved in development of curriculum for
- Neuroendocrine neoplasm specialist's curriculum for European Neuroendocrine Tumor Society / UEMS
- Radiomolecular Precision Oncology Curriculum for the International Center of Precision Oncology Academy
- Perceptorships for European Society for Medical Oncology
- Involved in training and mentoring of PhD students, MD PhD students, fellows.
- Development of graduate medical school student's curriculum.
Available to Mentor:
- PhD/MSTP Students
- Postdocs
- Residents and Fellows
Fingerprint
Dive into the research topics where Vikas Prasad is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Editorial: Bridging the gap to molecular imaging and theranostics
More, S., Sathekge, M. & Prasad, V., 2024, In: Frontiers in Nuclear Medicine. 4, 1385097.Research output: Contribution to journal › Editorial
Open Access -
Patlak Slope versus Standardized Uptake Value Image Quality in an Oncologic PET/CT Population: A Prospective Cross-Sectional Study
Ince, S., Laforest, R., Itani, M., Prasad, V., Ashrafinia, S., Smith, A. M., Wahl, R. L. & Fraum, T. J., May 2024, In: Diagnostics. 14, 9, 883.Research output: Contribution to journal › Article › peer-review
Open Access -
Use and perceived utility of [18F]FDG PET/CT in neuroendocrine neoplasms: A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022
Ambrosini, V., Caplin, M., Castaño, J. P., Christ, E., Denecke, T., Deroose, C. M., Dromain, C., Falconi, M., Grozinsky-Glasberg, S., Hicks, R. J., Hofland, J., Kjaer, A., Knigge, U. P., Kos-Kudla, B., Koumarianou, A., Krishna, B., Lamarca, A., Pavel, M., Reed, N. S. & Scarpa, A. & 4 others, , Jan 2024, In: Journal of Neuroendocrinology. 36, 1, e13359.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Use of approved Lu-177 radiopharmaceuticals in patients with end-stage renal disease: A review of the literature and proposed treatment algorithm
Trikalinos, N. A., Kim, H., Vijayan, A., Amurao, M. & Prasad, V., Jun 2024, In: Journal of Neuroendocrinology. 36, 6, e13393.Research output: Contribution to journal › Article › peer-review
-
177Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate Cancer and prior 223Ra (RALU Study)
Rahbar, K., Essler, M., Eiber, M., La Fougere, C., Prasad, V., Fendler, W. P., Rassek, P., Hasa, E., Dittmann, H., Bundschuh, R. A., Pabst, K. M., Kurtinecz, M., Schmall, A., Verholen, F. & Sartor, O., 2023, In: Journal of Nuclear Medicine. 64, 12, p. 1925-1931 7 p.Research output: Contribution to journal › Article › peer-review
Open Access5 Scopus citations